Synonyms: Cytosar® | DepoCyte® | U-19920
cytarabine is an approved drug (FDA (1969), EMA (2001))
Compound class:
Synthetic organic
Comment: Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
|
|
No information available. |
Summary of Clinical Use ![]() |
Cytarabine is used to treat some types of leukemia including leukemia associated with meningitis. In August 2017 the US FDA approved a fixed-dose combination of cytarabine and daunorubicin (Vyxeos®) for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |